Citi Raises AstraZeneca Earnings Forecast and Maintains 'Buy' Rating Ahead of Second-Half Pipeline Catalysts

Citi has raised its 2026 core earnings per share forecast for AstraZeneca by 2% to $10.30 following the company's first-quarter beat and maintained a 'buy' rating. The bank highlights positive risk-reward dynamics ahead of key second-half pipeline catalysts, including trials for Wainua, camizestrant, and Datroway.

By Proactive Thu, April 30, 2026 at 3:32 PM GMT+3 2 min read · Yahoo Finance · April 30, 2026, 12:32 UTC

Tickers: $AZN

Topics: Analyst Rating AstraZeneca Earnings Forecast Pharmaceuticals Pipeline Catalysts

Read the full article at Yahoo Finance

More World news

Parsons Reports Strong Third Quarter Results Driven by High-Margin Product Shift Motley Fool · November 12, 2026, 18:45 UTC
C.H. Robinson Reports Q3 2026 Earnings Driven by AI Efficiency and Margin Expansion Motley Fool · November 12, 2026, 18:45 UTC
Baker Hughes Raises Guidance Amid Surging Data Center Power Demand Motley Fool · November 12, 2026, 18:45 UTC
California Supreme Court to Rule on Insurance Overcharge Liability Under Proposition 103 PR Newswire · November 12, 2026, 18:44 UTC
Federal Court Orders Veterans Guardian to Pay Treble Damages to Disabled Veteran Class PR Newswire · November 12, 2026, 18:41 UTC
AIRO Group Holdings Reaffirms 2026 Revenue Growth Guidance Amid $200 Million Drone Backlog Seeking Alpha · November 12, 2026, 18:40 UTC
Nvidia CEO Jensen Huang Resigns Amid Personal Scandal, Raising Uncertainty for Open Source AI Strategy TechCrunch · November 12, 2026, 18:39 UTC
Vor Bio and RemeGen Expand Collaboration for Autoimmune Disease Therapy Seeking Alpha · November 12, 2026, 18:35 UTC
EnterpriseDB Hires CMRD Engineering Team to Strengthen Sovereign AI Governance PR Newswire · November 12, 2026, 18:36 UTC
Alliant Credit Union Executive Meredith Ritchie Named 2027 Chicago Titan 100 Honoree PR Newswire · November 12, 2026, 18:36 UTC